An Open-Label, Randomized, Single-Dose, Semi-Replicate, 4-Period, Crossover, Bioequivalence Study Comparing Two Tablet Formulations of Tebipenem Pivoxil Hydrobromide (TBPM-PI-HBr) in Healthy Adult Subjects
Latest Information Update: 22 Feb 2022
At a glance
- Drugs Tebipenem pivoxil (Primary)
- Indications Haemophilus infections; Streptococcal infections; Urinary tract infections
- Focus Pharmacokinetics
- Sponsors Spero Therapeutics
Most Recent Events
- 16 Sep 2021 According to a Spero Therapeutics media release, data from the study will be presented at the Infectious Disease Society of America (IDSA) IDWeekTM 2021.
- 10 Aug 2020 Status changed from recruiting to completed.
- 10 Jun 2020 New trial record